A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit the original URL.
The file type is application/pdf
.
Assessing the safety profile of antisense therapeutics through a novel computational and analytical framework
2018
With many safety and technical limitations partly mitigated through chemical modifications, antisense oligonucleotides (ASOs) are gaining recognition as therapeutic entities. The increased potency realised by 'third generation chemistries' may, however, simultaneously increase affinity to unintended targets with partial sequence complementarity. Hybridisation-dependent off-target effects (OTEs), a risk historically regarded as low, are not being adequately investigated. My data shows an
doi:10.25560/61019
fatcat:damgrue5k5fvlf566y3prnrtpu